http://www.ncbi.nlm.nih.gov/pubmed/23244777

Cancer Treat Rev. 2012 Dec 11. pii: S0305-7372(12)00236-8. doi: 10.1016/j.ctrv.2012.11.004. [Epub ahead of print]

Second Italian Consensus Conference on Malignant Pleural Mesothelioma: State of the art and recommendations.

Pinto C, Novello S, Torri V, Ardizzoni A, Betta PG, Bertazzi PA, Casalini GA, Fava C, Fubini B, Magnani C, Mirabelli D, Papotti M, Ricardi U, Rocco G, Pastorino U,Tassi G, Trodella L, Zompatori M, Scagliotti G.

Source

Medical Oncology Unit, S.Orsola-Malpighi Hospital, Bologna, Italy. Electronic address: carmine.pinto@aosp.bo.it.

Abstract

Malignant pleural mesothelioma (MPM) is a relevant public health issue. A large amount of data indicate a relationship between mesothelioma and asbestos exposure. MPM incidence has considerably and constantly increased over the past two decades in industrialized countries and is expected to peak in 2010-2020. In Italy, the standardized incidence rate in 2008 was 3.6 and 1.3 per 100,000 in men and women respectively, with wide differences from one region to another. The approach to this disease remains difficult and complex in terms of pathogenic mechanism, diagnosis, staging and treatment thus an optimal strategy has not yet been clearly defined. The Second Italian Multidisciplinary Consensus Conference on Malignant Pleural Mesothelioma was held in Turin (Italy) on November 24-25, 2011: recommendations on MPM management for public health institutions, clinicians and patients are presented in this report.